ClinicalTrials.gov record
Withdrawn Phase 2 Interventional

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

ClinicalTrials.gov ID: NCT00003405

Public ClinicalTrials.gov record NCT00003405. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon

Study identification

NCT ID
NCT00003405
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rush University Medical Center
Other
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

  • amifostine trihydrate Drug
  • bromodeoxyuridine Drug
  • cytarabine Drug
  • idarubicin Drug
  • idoxuridine Drug
  • isotretinoin Drug
  • mitoxantrone hydrochloride Drug
  • recombinant interferon alfa Biological

Drug · Biological

Eligibility (public fields only)

Age range
0 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 1998
Primary completion
Mar 31, 1999
Completion
Mar 31, 1999
Last update posted
Oct 13, 2021

1998 – 1999

United States locations

U.S. sites
4
U.S. states
1
U.S. cities
2
Facility City State ZIP Site status
Cook County Hospital Chicago Illinois 60612-9985
Rush Cancer Institute Chicago Illinois 60612
Angelo P. Creticos, M.D. Cancer Center Chicago Illinois 60657
Rush-Riverside Cancer Center Kankakee Illinois 60901

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003405, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2021 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003405 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →